Please login to the form below

Not currently logged in
Email:
Password:

Lexicon

This page shows the latest Lexicon news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Sanofi’s oral type 1 diabetes drug

FDA starts review of Sanofi’s oral type 1 diabetes drug

According to Lexicon, sotagliflozin is also being tested in type 2 diabetes with phase III results due in 2019. ... Lexicon exercised an option to co-promote the drug in the US  for the treatment of type 1 diabetes last year.

Latest news

  • Ipsen searches for new CEO after splitting top roles Ipsen searches for new CEO after splitting top roles

    Ipsen licenses the drug from Lexicon Pharmaceuticals and has rights outside the US and Japan.

  • Sanofi and Lexicon collaborate on new medication for diabetes Sanofi and Lexicon collaborate on new medication for diabetes

    Sanofi and Lexicon collaborate on new medication for diabetes. Plan to develop new investigational drugsotagliflozin. ... Pascale Witz, executive VP at Sanofi, said: “ This agreement with Lexicon reinforces our commitment to helping people living with

  • Jon Linscott: If I could change one thing... Jon Linscott: If I could change one thing...

    While integration, engagement and digital have been exciting additions to the marketer's lexicon we must not forget the language of our customers - which is value, choice and patient-centred.

  • Lexicon announces IBS trial results

    Lexicon announces IBS trial results. Lexicon Pharmaceuticals’ TPH inhibitor LX1031 has been shown in a phase II trial to be well tolerated and provide clinical benefit to patients with irritable bowel ... doses. Lexicon now intends to advance LX1033

  • Speaking of value

    Value demonstration should be based on a consistent lexicon for communicating the performance of medicines.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Communication is the key to unlocking the potential of immuno-oncology Communication is the key to unlocking the potential of immuno-oncology

    Marje Isabelle, Founder and CEO, Fertile Matters. This means working with others to define a new lexicon for cancer care; helping healthcare professionals stay on top of the deluge of new

  • Six degrees of participation Six degrees of participation

    Similarly, social listening is a great way of understanding the patient lexicon.

  • Asthma: beyond the blue and the brown Asthma: beyond the blue and the brown

    Indeed, it challenges the validity of the term ‘asthma’in the modern day medical lexicon at all.

  • Deal Watch November 2016 Deal Watch November 2016

    Strategic alliance, options. 122.7 per. BMS/ Lexicon Pharmaceuticals. BMS-986176 for neutopathic pain (pc) plus other small molecules that act on same target.

  • Deal Watch November 2015 Deal Watch November 2015

    Under the agreement Lexicon receives an upfront payment of $300m with a further $1.4bn in development, regulatory and sales milestones. ... Lexicon will continue to lead the development programme and has retained commercial rights to type 1 diabetes in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics